Literature DB >> 301157

Sequential quantitation of circulating immune complexes in syngeneic and allogeneic rats bearing Moloney sarcomas.

J C Jennette, J D Feldman.   

Abstract

A Raji cell radioimmunoassay was employed to quantitate serially circulating immune complexes (CIC) in the sera of syngeneic BN rats and allogeneic Lewis rats bearing BN Moloney sarcomas. In syngeneic BN hosts the levels of CIC attained and the time-course of detection were related to the tumor dose, tumor mass, and regressive or progressive course of the tumor. In general, syngeneic rats that received larger tumor doses developed larger tumors and greater maximum levels of CIC. However, the amount of CIC was not always directly proportional to the tumor size, although this was nearly the case with regressor BN and Lewis rats. In rats with regressing tumors, CIC decreased to insignificant levels as the tumors disappeared. Progressor BN rats that received 20 and 10 X 10(6) tumor cells had higher and more sustained levels of CIC, but, shortly before the hosts died, despite an increase of tumor size, there was a decline of CIC. Progressor BN rats that received an initial inoculum of 0.5 X 10(6) tumor cells that grew to 44 mm maximum mean diameter had levels of CIC which were only slightly above levels of control rats. All allogeneic Lewis hosts rejected BN Moloney sarcomas, but had transient low levels of CIC coincident with tumor growth. Lewis rats had lower levels of CIC than BN rats bearing comparable masses of sarcoma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 301157

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Suppressor mechanisms in tumor immunity.

Authors:  G T Nepom; I Hellström; K E Hellström
Journal:  Experientia       Date:  1983-03-15

2.  [Clinical significance of circulating immune complexes in patients with metastatic breast cancer].

Authors:  G Krieger; A Kehl; I Bause; M Kneba; G A Nagel
Journal:  Klin Wochenschr       Date:  1982-12-01

3.  Isolation of circulating immune complexes using Raji cells. Separation of antigens from immune complexes and production of antiserum.

Authors:  A N Theofilopoulos; R A Eisenberg; F J Dixon
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

4.  Relationship of serum alpha-fetoprotein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma.

Authors:  J F Tsai; J H Tsai; W Y Chang
Journal:  Gastroenterol Jpn       Date:  1990-06

5.  Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate.

Authors:  R Bhatti; P Ray; N Bell
Journal:  Urol Res       Date:  1991

6.  Immune complexes with antiglobulin activity in sera of Moloney sarcoma-bearing rats.

Authors:  J R Balint
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

7.  Consistent fluctuations in quantities of circulating immune complexes during progressive and regressive phases of tumor growth.

Authors:  J C Jennette
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

8.  IgA containing immune complexes in dogs bearing a spontaneous mammary adenocarcinoma.

Authors:  J Balint; T Nagai; Y Ikeda; K Meek; D S Terman
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

9.  Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer.

Authors:  K A Chester; R H Begent
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

10.  Adoptive T cell immunotherapy of MSV-induced tumours in nude mice. Part II. Sequential analysis of serum immune complexes and blocking activity in reconstituted mice in relation to tumour biology.

Authors:  D F Tucker; R A Knight; P H Warne
Journal:  Clin Exp Metastasis       Date:  1983 Jul-Sep       Impact factor: 5.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.